This may serve as an attractive STAT5 inhibitor not only for FLT3/ITD+ AML but more broadly for other leukemia and myeloproliferative neoplasms with constitutive STAT5 activation to be tested in future studies. The gene discussed is FLT3; the disease is myeloproliferative disorder.